Observational Study of Long-term Safety and Efficacy of Subjects Who Participated in CS10BR05 Inj. Phase 1 Study
Latest Information Update: 14 Jan 2025
At a glance
- Drugs CS 10BR05 (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors CORESTEM; Corestemchemon
Most Recent Events
- 07 Jan 2025 Status changed from active, no longer recruiting to completed.
- 03 Jan 2022 New trial record